Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  DRG Market Assessment Reports

Prostate Cancer | Current Treatment | Physician Insights | EU5 | 2017

Login to access report north_east
Contact sales account_box

Hormonal therapy is the mainstay of prostate cancer, in all stages of disease and clinical settings. The adoption of novel hormonal agents, Zytiga (Johnson & Johnson/Janssen) and Xtandi (Pfizer/Astellas), for metastatic castrate-resistant disease has driven considerable growth in the size of the prostate cancer market. Penetration of Zytiga and Xtandi (and other novel hormonal agents) in other patient populations (e.g., biochemical recurrent, non-metastatic castrate-resistant disease) will be major market drivers. Other therapies, including Xofigo (Bayer HealthCare) and Jevtana (Sanofi) offer non-hormonal treatment options. However, optimal sequencing of therapies in the crowded castrate resistant prostate cancer armamentarium is still under reconnaissance.

Questions Answered:

  • How does treatment differ, if at all, between biochemically recurrent and non-metastatic castrate resistant prostate cancer patients? What secondary hormone manipulations, if any, are employed?
  • What is the most preferred sequencing of treatment among the asymptomatic, and symptomatic metastatic castrate resistant prostate cancer patients?
  • What are the main key drivers and obstacles to prescribing of the current therapies in the treatment of metastatic castrate-resistant prostate cancer?
  • How does treatment duration of key therapies (e.g., LHRH agonists, Zytiga, and Xtandi) differ by clinical setting (e.g., newly diagnosed patients vs. biochemical recurrent vs. castrate-resistant) according to surveyed physicians?

Markets covered: France, Germany, Italy, Spain, United Kingdom.

Primary research: Survey of 250 European oncologists and urologists (~50 in each of the EU5 countries) fielded in February 2017.

Key companies: Johnson & Johnson, Astellas Pharma (Medivation), Bayer Healthcare, Sanofi-Aventis

Key drugs: Xtandi, Xofigo, Jevtana, Zytiga

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Opioid-Induced Constipation – Current Treatment – Treatment Algorithms: Claims Data Analysis – Opioid-Induced Constipation (US)
Opioid-induced constipation (OIC) is a condition in which bowel movements are infrequent or incomplete because of opioid medications. The treatment of OIC relies on various prescription medications…
north_east
Report
Migraine – Current Treatment – Treatment Algorithms: Claims Data Analysis – Migraine Prophylaxis (US)
Migraine is a common neurological condition characterized by moderate to severe headaches; it can have a major impact on patients’ quality of life. Our quantitative analysis of treatment patterns…
north_east
Report
Vitiligo – Current Treatment – Treatment Algorithms: Claims Data Analysis – Vitiligo (US)
Vitiligo is a chronic skin depigmentation disorder characterized by the destruction or functional loss of melanocytes. Given its visible manifestations, the disease is associated with a substantial…
north_east
Report
Human Immunodeficiency Virus – Current Treatment – Treatment Algorithms: Claims Data Analysis – Human Immunodeficiency Virus (US)
The HIV therapy market is crowded with several approved ARVs. Market growth is driven by the increasing acceptance of new, high-priced ARVs, particularly the latest STRs, which offer improved…
north_east
Report
Major Depressive Disorder (DSM-V) – Current Treatment – Treatment Algorithms: Claims Data Analysis – Major Depressive Disorder (US)
Major depressive disorder (MDD) is a widely drug-treated condition managed with multiple drug classes, most commonly selective serotonin reuptake inhibitors (SSRIs), serotonin–norepinephrine…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east